Research digest — investigational compound
Retatrutide: one molecule, three receptor targets, and the trial record that made the difference.
In Phase 2, 12 mg once weekly produced a mean -24.2% body-weight change over 48 weeks — a number that rewrote expectations for incretin-based therapy. This site is a digest of every published study behind that number.
The short version
Retatrutide is an experimental drug being studied for obesity and type 2 diabetes. It has not been approved by the FDA or any other regulator — it is still in large Phase 3 clinical trials as of 2026. What makes it different from other drugs in this class is that it activates three separate hormone receptors at once: GLP-1, GIP (two gut hormones that help control blood sugar and appetite), and glucagon (a liver hormone that raises energy burn). Most comparable drugs only target one or two of those receptors. In clinical trials, the combination produced larger weight loss than any prior drug of this type had shown. In a 48-week study of adults with obesity, the highest dose studied produced an average 24% reduction in body weight — roughly comparable to bariatric surgery in terms of the number alone, though the two interventions work very differently. The trials also documented real risks: nausea and other gut side effects are common, heart rate increases measurably at higher doses, and no one yet knows what happens to weight or health once someone stops taking it. This site summarizes what the published studies have actually found and what people in research-use communities report — including the downsides — which is on the Retatrutide effects page.
What does retatrutide do
Retatrutide (also known by its development code LY3437943) is a 39-amino-acid synthetic peptide developed by Eli Lilly. It is the first investigational compound to activate all three of the main incretin- and glucagon-axis receptors — GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor) — with a single molecule [1]. The GLP-1 arm suppresses appetite and enhances insulin secretion after meals. The GIP arm adds insulinotropic (insulin-stimulating) and adipose (fat-tissue) metabolic effects. The glucagon arm — the novel addition that distinguishes this compound from dual agonists like tirzepatide — activates the liver's energy-expenditure circuitry and drives lipid mobilization, the breakdown of stored fat for fuel.
The result, across how does retatrutide work as the Phase 1 and Phase 2 data progressively established, is a weight-loss effect substantially larger than either single or dual agonists had produced. In the pivotal 48-week Phase 2 obesity trial (338 adults, BMI ≥30), once-weekly subcutaneous retatrutide at 12 mg produced a mean body-weight change of -24.2% versus -2.1% with placebo [1]. Participants with type 2 diabetes in a parallel 36-week Phase 2 trial showed -16.94% body weight at 36 weeks and HbA1c (glycated hemoglobin, a marker of average blood-glucose control) reduction of -2.02% with 12 mg versus -0.01% with placebo [2].
That degree of efficacy repositioned the conversation around what non-surgical weight management could achieve. A 2024 review in Cell described triple-receptor agonism as capable of weight losses up to ~20-30%, "rivaling bariatric surgery" in magnitude through purely pharmacological means [10].
Retatrutide results — the Phase 2 numbers
Three Phase 2 populations have now been studied. In obesity without diabetes, the 48-week trial is the headline: -24.2% body weight, with nearly 20 cm waist circumference reduction at the highest dose, and dose-dependent benefit down to -8.7% at 1 mg [1]. In type 2 diabetes, the 36-week trial documented -16.94% body weight alongside meaningful glycemic improvement [2]. In metabolic dysfunction-associated steatotic liver disease (MASLD — formerly called NAFLD, and defined as excess liver fat tied to metabolic risk factors), a 48-week substudy found retatrutide 12 mg reduced liver fat by -82.4% at 24 weeks, with 86% of participants reaching normal liver fat content (below 5% by MRI-PDFF, a non-invasive imaging measure of liver fat) [5].
The first-in-human Phase 1b study in type 2 diabetes established the pharmacokinetic (drug-behavior) profile: a half-life of approximately 6 days supports once-weekly dosing, and placebo-adjusted weight loss reached -8.96 kg over just 12 weeks at the highest dose tested [4]. A 2025 review in Biomolecules characterized the up-to ~24% weight loss as a "step-change versus prior incretin therapies" [6]. The Phase 3 TRIUMPH program — covering obesity, type 2 diabetes, cardiovascular outcomes, chronic kidney disease, and a head-to-head comparison with tirzepatide — is ongoing as of mid-2026, and no Phase 3 results have been published.
Is retatrutide fda approved
No. Retatrutide is not approved by the FDA or any regulatory agency as of 2026. It is an investigational new drug being studied in Phase 3 clinical trials under Eli Lilly's TRIUMPH program [6]. It is not available as a prescription product, and there is no approved formulation, labeled dose, or approved indication for any patient population.
The domain name of this site is an SEO artifact — this site is an independent research digest of the published literature. It does not sell, dispense, prescribe, or recommend retatrutide in any form. Anyone using research-labeled retatrutide obtained outside a clinical trial is using an unregulated product with no verified identity, purity, or sterility [caution 1 from safety data].
Retatrutide availability: Because Phase 3 trials are ongoing and no NDA (New Drug Application) has been filed or approved, retatrutide is not commercially available. When will retatrutide be available depends on the Phase 3 data and a subsequent FDA review process — a realistic horizon, if TRIUMPH data are positive and Eli Lilly files an NDA, would be 2027-2028, though no approval date has been announced.
Retatrutide vs tirzepatide
The structural comparison is: tirzepatide is a dual agonist (GIP + GLP-1 receptors); retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptors). The additional glucagon receptor arm is the pharmacological difference that researchers believe accounts for retatrutide's larger observed weight loss [1][10]. In the Phase 2 obesity trial, retatrutide's -24.2% exceeds the approximately -20% seen with the highest tirzepatide doses in its comparable SURMOUNT-1 trial data. Phase 2 head-to-head comparisons between the two molecules do not yet exist; the TRIUMPH-4 trial includes an active-comparator arm vs tirzepatide, but results are not yet available. A 2024 comparative review positioned retatrutide among the highest-efficacy agents across seven GLP-1 receptor agonists and polyagonists studied for weight loss [8].
Crucially, neither tirzepatide's nor retatrutide's weight-loss numbers translate into a direct "X is better than Y" recommendation — they are different drugs with different safety profiles, dosing, and approval statuses. Tirzepatide is approved; retatrutide is investigational. A Retatrutide research review of the mechanism explains why the glucagon arm matters physiologically.